Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk vetenskap, Psykiatri.
Visa övriga samt affilieringar
2019 (Engelska)Ingår i: Frontiers in Psychiatry, ISSN 1664-0640, E-ISSN 1664-0640, Vol. 10, artikel-id 592Artikel, forskningsöversikt (Refereegranskat) Published
Abstract [en]

Opioid use disorder (OUD) is a major public health issue that has reached epidemic levels in some parts of the world. It is a chronic and complex neurobiological disease associated with frequent relapse to drug taking. Craving, defined as an overwhelmingly strong desire or need to use a drug, is a central component of OUD and other substance use disorders. In this review, we describe the neurobiological and neuroendocrine pathways that underpin craving in OUD and also focus on the importance of assessing and treating craving in clinical practice. Craving is strongly associated with patients returning to opioid misuse and is therefore an important treatment target to reduce the risk of relapse and improve patients' quality of life. Opioid agonist therapies (OAT), such as buprenorphine and methadone, can significantly reduce craving and relapse risk, and it is essential that patients are treated optimally with these therapies. There is also evidence to support the benefits of non-pharmacological approaches, such as cognitive behavioral therapy and mindfulness-based interventions, as supplementary treatments to opioid agonist therapies. However, despite the positive impact of these treatments on craving, many OUD patients continue to suffer with negative affect and dysphoria. There is a clear need for further studies to progress our understanding of the neurobiological basis of craving and addiction and to identify novel therapeutic strategies as well as to optimize the use of existing treatments to improve outcomes for the growing numbers of patients affected by OUD.

Ort, förlag, år, upplaga, sidor
Frontiers Media S.A., 2019. Vol. 10, artikel-id 592
Nyckelord [en]
opioid, craving, addiction, negative affect, methadone, buprenorphine
Nationell ämneskategori
Beroendelära
Identifikatorer
URN: urn:nbn:se:umu:diva-163664DOI: 10.3389/fpsyt.2019.00592ISI: 000483324900001OAI: oai:DiVA.org:umu-163664DiVA, id: diva2:1362856
Tillgänglig från: 2019-10-21 Skapad: 2019-10-21 Senast uppdaterad: 2019-10-21Bibliografiskt granskad

Open Access i DiVA

fulltext(1777 kB)19 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 1777 kBChecksumma SHA-512
29c3cc0762388db37490a52bc4fc140fd6ebe1f2eead1c6b0f05522cd7581d38563c969eede0e159e214810c341ae29958dbc5f66f87d80edcece8a2743c932b
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltext

Sök vidare i DiVA

Av författaren/redaktören
Kakko, Johan
Av organisationen
Psykiatri
I samma tidskrift
Frontiers in Psychiatry
Beroendelära

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 19 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 45 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf